High-Dose CoQ10 Research Urged In UCSD Early Parkinson’s Study
This article was originally published in The Tan Sheet
Executive Summary
Early-stage Parkinson's disease patients given 1,200 mg/day coenzyme Q10 experienced slower disease progression than those receiving 300 mg/d, 600 mg/d or placebo, a recent Phase II study found
You may also be interested in...
CoQ10 Early-Stage Parkinson's Disease Trial Nearing Completion
A prospective, randomized, double-blind clinical trial examining coenzyme Q10's effectiveness at treating Parkinson's disease will be completed this month, with results slated for release at the end of the year.
Enzymatic Therapy
Three products added to firm's heart health line, including Vitaline CoQ10, Vitaline L-Carnitine and Eskimo 3, a fish oil supplement. Line also includes Heart Health Formula, Formula to Retain Healthy Cholesterol Levels and Allicin 5000, a once-a-day garlic supplement. Updated packaging for the line features guidelines to help consumers determine their own dosage level. A print ad campaign for Vitaline CoQ10 is scheduled to begin in May and will run through year end. A 30-count of 100 mg Vitaline CoQ10 chews in chocolate and maple flavors will retail for $34.50. A 60-count of Vitaline L-Carnitine softgels will sell for $36.95 and 105 Eskimo-3 softgels will cost $19.95
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC